Remus Pharmaceuticals Limited
Remus Pharmaceuticals Limited scores highest on Nitro (96) and lowest on Price (29). Its PosiPenta is 64.32 out of 100, better than most similar companies.
On the Penta Grid this week, Remus Pharmaceuticals Limited is Grid #170 of 2,356 in India.
Compared with similar companies in India.
The five pillars
Details
PPrice
| P/E ratio | 48.77 |
| P/B ratio | 3.36 |
EEarnings
| Trailing EPS | — |
| Forward EPS | — |
NNitro
| Price | 1002.00 |
| 52-week high | 1039.00 |
| 52-week low | 580.00 |
| Fall from 52-week high | 3.6% |
TTorque
| Return on equity (ROE) | — |
| Debt-to-equity | 0.08 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹1,180 Cr |
| Promoter holding | 70.95% |
| Dividend yield | — |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Remus Pharmaceuticals Limited's PosiPenta score?
Remus Pharmaceuticals Limited's PosiPenta is 64.32 out of 100 for the week of 17 Oct 2026, based on 4 of 5 pillars.
Where does Remus Pharmaceuticals Limited stand on the Penta Grid?
On the Penta Grid this week, Remus Pharmaceuticals Limited is Grid #170 of 2,356 in India.
Which PosiPenta pillar is strongest for Remus Pharmaceuticals Limited?
Nitro (momentum), with a score of 96 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Remus Pharmaceuticals Limited?
Price (valuation), with a score of 29 out of 100: weaker than most similar companies.
Has Remus Pharmaceuticals Limited's PosiPenta changed since last week?
Yes, it fell 0.20 points, from 64.52 to 64.32.
PositoAI is for research and education only and is not investment advice.